7News Just In
Von Hippel-Lindau disease is a rare hereditary condition affecting hundreds of Australians, causing recurring tumours throughout the body with no cure available. The breakthrough drug Belzutifan has transformed treatment for patients like Lana Hallowes, eliminating the need for constant surgeries and offering hope for the future. The medication, now listed on the Pharmaceutical Benefits Scheme for $25 per month, previously cost up to $12,000 monthly, though advocates emphasise the need for continued research into neuroendocrine cancers. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.
1000 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der 7News Just In-Community!